Ocular Therapeut - OCUL STOCK NEWS

Ocular Therapeutix (NASDAQ: OCUL) reported Q3 2024 financial results and business updates. The company achieved total net revenue of $15.4 million, a 2.3% increase from Q3 2023. Cash position stands at $427.2 million, expected to fund operations into 2028. The Phase 3 SOL-1 trial for AXPAXLI in wet AMD is expected to complete randomization by year-end 2024, with topline data anticipated in Q4 2025. The company reported a net loss of $36.5 million or $(0.22) per share. Full-year 2024 DEXTENZA revenue guidance is projected between $62.0-67.0 million.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in two major healthcare events. The company will present at the Jefferies London Healthcare Conference on November 20, 2024, featuring a fireside chat at 9:00 AM GMT, which will be accessible via webcast on the company's investor website.

Additionally, the company will participate in the Ophthalmology Innovation Summit XIV in San Diego on November 22-23, 2024. The event will feature three sessions: a Retina Innovation Showcase presented by Chief Strategy Officer Sanjay Nayak, a Glaucoma Spotlight panel featuring Board Member Adrienne Graves, and 'A View From The Street' panel moderated by CEO Pravin U. Dugel.

Ocular Therapeutix (NASDAQ: OCUL) has appointed Namrata Saroj, OD, as Chief Business Officer (CBO). Dr. Saroj, who previously served as Development Strategy Consultant since February 2024, brings over 20 years of experience in ophthalmic drug development and commercialization. She has contributed to successful FDA-approved drugs including LUCENTIS® and EYLEA®, and has been instrumental in executing Ocular's registrational program for AXPAXLI™ in wet age-related macular degeneration. Dr. Saroj's expertise spans clinical development, trial enrollment, launch preparation, and commercialization support across various stages of pharmaceutical development.

Ocular Therapeutix (NASDAQ:OCUL) has scheduled its third quarter 2024 financial results conference call and webcast for Thursday, November 14, 2024, at 8:00 AM ET. The company will discuss business progress and financial results for the quarter ended September 30, 2024. The event will be accessible via phone and webcast, with U.S. participants dialing 1-877-407-9039 and international participants using 1-201-689-8470. A replay will be available on the company's website for at least 30 days.

Ocular Therapeutix has announced accelerated timelines for its SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The company now expects:

• Full enrollment and randomization by the end of 2024
• Topline data during the fourth quarter of 2025

SOL-1 is a superiority study conducted under a Special Protocol Agreement with the FDA, aiming to randomize approximately 300 subjects. The primary endpoint is the proportion of subjects maintaining visual acuity at Week 36. The ongoing Phase 3 clinical program, including SOL-1 and SOL-R studies, is expected to form the basis for AXPAXLI's regulatory filing for wet AMD treatment.

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on developing innovative therapies for retinal diseases and other eye conditions, has announced inducement awards for its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:

1. Non-statutory stock options to purchase up to 296,500 shares of Ocular's common stock at the closing price on October 7, 2024. These options have a ten-year term and vest over four years.

2. Restricted stock unit awards representing 98,700 shares of Ocular's common stock, vesting over three years in equal annual installments.

These inducement equity awards are subject to Mr. Anderman's continued service with Ocular and the terms of the 2019 Inducement Stock Incentive Plan.

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in the UBS Virtual Opthalmology Day 2024. The event will feature a fireside chat with Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular, scheduled for Wednesday, October 2, 2024, at 3:00 PM ET.

The company, which focuses on developing innovative therapies for retinal diseases and other eye conditions, will also host investor meetings during the conference. Interested parties can access a live webcast of the fireside chat through the Investors section of Ocular's website at investors.ocutx.com.

This participation underscores Ocular Therapeutix's commitment to engaging with the investment community and sharing insights about its efforts to improve vision through advanced therapeutics.

Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on developing therapies for retinal diseases and eye conditions, has announced inducement awards for its newly appointed Director of IT Cybersecurity, Russell Isaacs. The awards, granted under Ocular's 2019 Inducement Stock Incentive Plan, include:

1. Non-statutory stock options: 14,000 shares at market price, vesting over four years
2. Restricted stock unit awards: 4,666 shares, vesting over three years

These equity awards are designed to incentivize Mr. Isaacs' employment with Ocular and are subject to his continued service with the company. The grants comply with Nasdaq Listing Rule 5635(c)(4) and were effective as of September 9, 2024.

Ocular Therapeutix (NASDAQ: OCUL) announces multiple presentations at four major retina meetings in Portugal and Spain this September. The presentations focus on their innovative therapies for retinal diseases, particularly the axitinib hydrogel implant (OTX-TKI) for treating neovascular age-related macular degeneration (AMD) and diabetic retinopathy.

Key presentations include:

• 52-week results of OTX-TKI in AMD patients at The Retina Society meeting
• One-year results of OTX-TKI in diabetic retinopathy from the HELIOS Phase 1 trial
• Panel discussions on novel drug delivery approaches for posterior segment diseases
• 48-week safety and efficacy results from the HELIOS trial for non-proliferative diabetic retinopathy

These presentations highlight Ocular's transformation into a retina-focused company and its efforts to change the future paradigm for managing retinal vascular diseases.